Drug target Mendelian randomization supports apolipoprotein C3-lowering for lipoprotein-lipid levels reductions and cardiovascular diseases prevention

Eloi Gagnon, Benoit J. Arsenault
doi: https://doi.org/10.1101/2023.11.04.23298088

Article Information

doi 
https://doi.org/10.1101/2023.11.04.23298088
History 
  • November 5, 2023.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

Author Information

  1. Eloi Gagnon, MA1 and
  2. Benoit J. Arsenault, PhD1,2,*
  1. 1Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec, Québec (QC), Canada
  2. 2Department of Medicine, Faculty of Medicine, Université Laval, Québec (QC), Canada
  1. ↵*Address for correspondence Benoit Arsenault, PhD, Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec — Université Laval, Y-3106, Pavillon Marguerite D’Youville, 2725 chemin Ste-Foy, Québec (QC), Canada G1V 4G5, Telephone: 418-656-8711 ext. 3498, Email: benoit.arsenault{at}criucpq.ulaval.ca
Back to top
Posted November 05, 2023.
Download PDF

Supplementary Material

Email
Drug target Mendelian randomization supports apolipoprotein C3-lowering for lipoprotein-lipid levels reductions and cardiovascular diseases prevention
Eloi Gagnon, Benoit J. Arsenault
medRxiv 2023.11.04.23298088; doi: https://doi.org/10.1101/2023.11.04.23298088
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area